Table 1 Demographics and characteristics of hospital stay per patient cluster of the Discovery cohort
From: Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity
Variable | Entries | All | 1 | 2 | 3 | 4 | Stats |
|---|---|---|---|---|---|---|---|
n | 242 | 38 | 49 | 73 | 82 | ||
Age | [median (IQR#)] | 66.4 (52.4 − 78.8) | 71.8 (64.4 − 78.8) | 66.9 (58.3 − 79.5) | 64.8 (54.1 − 82.0) | 57.6 (48.2 − 74.3) | 0.032 |
Sex | |||||||
Male | 141 (58%) | 25 (66%) | 27 (55%) | 38 (52%) | 51 (62%) | 0.43 | |
Female | 101 (42%) | 13 (34%) | 22 (45%) | 35 (48%) | 31 (38%) | ||
Max respiratory Support throughout hospital stay | |||||||
No O2 | 86 (36%) | 5 (13%) | 10 (20%) | 36 (49%) | 35 (43%) | 0.0001 | |
NC | 63 (26%) | 5 (13%) | 8 (16%) | 22 (30%) | 28 (34%) | 0.028 | |
NIV | 32 (13%) | 7 (18%) | 9 (18%) | 5 (7%) | 11 (13%) | 0.20 | |
ETI | 59 (24%) | 20 (53%) | 22 (45%) | 10 (14%) | 7 (9%) | <0.0001 | |
ECMO | 2 (1%) | 1 (3%) | 0 (9%) | 0 (0%) | 1 (1%) | 0.44 | |
Days of hospitalization [median (IQR)] | 14 (8.0 − 27.0) | 24 (10.0 − 36.0) | 19 (12 − 41.5) | 14 (7.0 − 25.0) | 9 (5.3 − 15.8) | <0.0001 | |
ICU admission | 89 (37%) | 27 (71%) | 29 (59%) | 15 (21%) | 18 (22%) | <0.0001 | |
Days in ICU [median (IQR)] | 14 (5.0 − 31.0) | 24 (8.5 − 34.0) | 19 (7.0 − 35.0) | 14 (9.0 − 25.5) | 4.5 (3.3 − 6.8) | 0.0003 | |
Metabolic risk factors | |||||||
None | 75 (31%) | 10 (26%) | 14 (29%) | 24 (33%) | 27 (33%) | 0.85 | |
One or more | 167 (69%) | 28 (74%) | 35 (71%) | 49 (67%) | 55 (67%) | ||
Obese | 33 (14%) | 5 (13%) | 12 (24%) | 10 (14%) | 6 (7%) | 0.053 | |
Hypertension | 139 (57%) | 26 (68%) | 30 (61%) | 41 (56%) | 42 (51%) | 0.32 | |
Dyslipidemia | 57 (24%) | 11 (29%) | 16 (33%) | 14 (19%) | 16 (20%) | 0.22 | |
Diabetes | 86 (36%) | 15 (39%) | 19 (39%) | 27 (37%) | 25 (30%) | 0.69 | |
Chronic diseases | |||||||
None | 99 (41%) | 9 (24%) | 19 (39%) | 32 (44%) | 39 (48%) | 0.089 | |
One or more | 143 (59%) | 29 (76%) | 30 (61%) | 41 (56%) | 43 (52%) | ||
Chronic Kidney Disease | 41 (17%) | 13 (34%) | 9 (18%) | 10 (14%) | 9 (11%) | 0.013 | |
Heart Failure | 51 (21%) | 11 (29%) | 11 (22%) | 15 (21%) | 14 (17%) | 0.52 | |
Respiratory Disease | 42 (17%) | 12 (32%) | 8 (16%) | 9 (12%) | 13 (16%) | 0.078 | |
Liver Disease | 21 (9%) | 7 (18%) | 5 (10%) | 6 (8%) | 3 (4%) | 0.63 | |
Immunosuppressed | 20 (8%) | 4 (11%) | 6 (12%) | 6 (8%) | 4 (5%) | 0.47 | |
Malignancy | 35 (14%) | 5 (13%) | 7 (14%) | 10 (14%) | 13 (16%) | 0.98 | |
HIV | 5 (2%) | 2 (5%) | 1 (2%) | 1 (1%) | 1 (1%) | 0.50 | |
Neurological disorder | 30 (12%) | 3 (8%) | 8 (16%) | 8 (11%) | 11 (13%) | 0.65 | |
Risk factors (Metabolic + Chronic) | |||||||
None | 40 (17%) | 4 (11%) | 9 (18%) | 13 (18%) | 14 (17%) | 0.75 | |
One or more | 202 (83%) | 34 (89%) | 40 (83%) | 60 (82%) | 68 (83%) | ||
Outcome | |||||||
Fatality DSO60 | 34 (14%) | 18 (47%) | 6 (12%) | 7 (10%) | 3 (4%) | <0.0001 | |
